About Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals is a company based in Pohang-si (South Korea) founded in 2021. Thyssen Biopharmaceuticals has raised $1.59 million across 1 funding round from investors including Envisioning Partners, Stonebridge Ventures and FuturePlay. Thyssen Biopharmaceuticals offers products and services including Cell-Grown Meat. Thyssen Biopharmaceuticals operates in a competitive market with competitors including Simple Planet, HN Novatech, Innohas, DaNAgreen and SEAWITH, among others.
- Headquarter Pohang-si, South Korea
-
Sectors
Consumer
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.59 M (USD)
in 1 rounds
-
Latest Funding Round
$1.59 M (USD), Seed
Sep 19, 2022
-
Investors
Envisioning Partners
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals offers a comprehensive portfolio of products and services, including Cell-Grown Meat.
Sustainable meat produced by cultivating animal cells without farming.
Funding Insights of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals has successfully raised a total of $1.59M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.59 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Envisioning Partners, Stonebridge Ventures and FuturePlay.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
No specific activity is described for this entity.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology and AI sectors are provided.
|
Locked | Locked | Locked | |
|
FuturePlay is engaged in startup investment and acceleration.
|
Locked | Locked | Locked |
Investor details for Thyssen Biopharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Thyssen Biopharmaceuticals
Investment portfolio details for Thyssen Biopharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Thyssen Biopharmaceuticals
Detailed financials for Thyssen Biopharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Thyssen Biopharmaceuticals Comparisons
Peer comparison for Thyssen Biopharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Simple Planet, HN Novatech, Innohas, DaNAgreen and SEAWITH, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of plant-based cultivated meat
|
|
| Locked | Locked | Locked |
Platform offering alternative meat products
|
|
| Locked | Locked | Locked |
Plant-based meat substitute novel food products are developed by Innohas.
|
|
| Locked | Locked | Locked |
Provider of scaffolds to culture cells in 3D
|
|
| Locked | Locked | Locked |
Cultured meat products are developed from seaweed using lab-based methods.
|
Detailed competitors of Thyssen Biopharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thyssen Biopharmaceuticals
Complete news archive for Thyssen Biopharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thyssen Biopharmaceuticals
Thyssen Biopharmaceuticals was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Thyssen Biopharmaceuticals is headquartered in Pohang-si, South Korea. It is registered at Pohang-si, North Gyeongsang Province, South Korea.
Wonil Han is the current CEO of Thyssen Biopharmaceuticals.
Thyssen Biopharmaceuticals is a funded company, having raised a total of $1.59M across 1 funding round to date.
Thyssen Biopharmaceuticals was established in 2021 as a biopharmaceutical entity. An online platform is maintained to distribute lab-grown meat substitutes produced through tissue engineering. Cultivated meat is manufactured in kilogram quantities, featuring realistic texture and marbling. Artificial organs for medical applications are also developed using similar technologies. Operations center on innovations in food alternatives and regenerative medicine, with details on geographic presence unavailable.
Thyssen Biopharmaceuticals's top competitors include Simple Planet, DaNAgreen and HN Novatech.
Thyssen Biopharmaceuticals offers Cell-Grown Meat.
Thyssen Biopharmaceuticals has 4 investors. Key investors include Envisioning Partners, Stonebridge Ventures, FuturePlay, and Mirae Holdings.